Neurology and Ophthalmology > Research >

Clinical Studies

Clinical Studies

Myasthenia Gravis

  1. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to 
    Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
  2. DNTH103‑MG‑201: A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety,
    Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults with Generalized Myasthenia Gravis (MAGIC)
  3. Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with gMG
  4. A Phase 2b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Myasthenia Gravis
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in  Patients with Generalized Myasthenia Gravis
  6. A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized Myasthenia Gravis, followed by an open-label extension phase
  7. MS700568_0183 (MyClad), A Phase 3, Randomized,  Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety  of a New Formulation of Oral Cladribine compared with Placebo in Participants with  Generalized Myasthenia Gravis
  8. A Phase 1b/2a Double Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of  CNP-106 in Subjects Ages 18–75 with Generalized Myasthenia Gravis
  9. Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

 

Chronic Inflammatory Demyelinating Polyneuropathy

  1. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
  2. A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants with Refractory Chronic Inflammatory Demyelinating Polyneuropathy
  3. A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart versus Intravenous Immunoglobulin (IVIg) in 
    Participants with Chronic Inflammatory Demyelinating Polyneuropathy

Migraine

  1. Pediatric Options for Migraine Relief: A randomized, double-blind, placebo-controlled study of
    lasmiditan for acute treatment of migraine: PIONEER-PEDS1 Study.
  2. A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients
    with Migraine – PIONEER-PEDS2
  3. Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine
  4. Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine

Thyroid Eye Disease

  1. A randomized, double-masked, placebo-controlled safety, tolerability, and efficacy study of VRDN-001, a humanized monoclonal antibody 
    directed against the IGF-1 receptor, in participants with chronic thyroid eye disease (TED)
  2. An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal studies
  3. A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants with Thyroid Eye Disease

Epilepsy

  1. A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to
    Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset
    Seizures
  2. A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
  3. A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of
    XEN1101 in Subjects Diagnosed With Epilepsy

 

Stroke

  1. A Phase 3, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of an Oral Factor XIa Inhibitor, after an Ischemic Stroke or High Risk Transient Ischemic Attack
  2. Phase 3 study to investigate the efficacy and safety of the oral FXIa inhibitor Asundexian (BAY 2433334) compared with placebo in participants after an acute noncardioembolic ischemic stroke or high-risk TIA (OCEANICStroke)

Parkinson’s Disease

  1. A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson’s Disease
  2. 58-Week Open-label Trial of Tavapadon in Parkinson’s Disease (TEMPO-4 Trial)
  3. A Randomized Placebo-controlled Trial of Zoledronic Acid for Prevention of Fractures in Patients with Parkinson’s Disease

Cervical Dystonia

  1. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of MTR-601, a Novel Oral Treatment in Patients with Cervical Dystonia.

Alzheimer’s Disease

  1. Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment with Either Suspected Chronic Traumatic Encephalopathy or Alzheimer’s Disease

If interested in study participation, please contact:

Aubrey Alexander, CCRC
Clinical Research Manager
Department of Neurology
Phone: 517-884-8920
Email: alexaub@msu.edu